Our understanding of hepatitis B trojan (HBV) reactivation during immunosuppresive therapy has increased remarkably during modern times. For rituximab a potential study confirmed the 2-calendar year cumulative threat of reactivation to become 41.5% but prospective data continues to be lacking for other immunosupressive regimes. The perfect management in stopping HBV reactivation would involve suitable risk… Continue reading Our understanding of hepatitis B trojan (HBV) reactivation during immunosuppresive therapy